Sullivan Timothy Eugene 4
4 · Apellis Pharmaceuticals, Inc. · Filed Jan 3, 2025
Insider Transaction Report
Form 4
Sullivan Timothy Eugene
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-12-31$14.95/sh+1,042$15,578→ 80,216 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-31−10,054→ 84,946 totalExercise: $13.85Exp: 2029-02-07→ Common Stock (10,054 underlying) - Exercise/Conversion
Common Stock
2024-12-31$13.85/sh+10,054$139,248→ 90,270 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-12-31−1,042→ 23,958 totalExercise: $14.95Exp: 2028-02-15→ Common Stock (1,042 underlying)
Holdings
- 70,396(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]The securities are held by The Timothy E Sullivan Irrevocable Trust of 2023. Patrick O. Collins is the trustee of The Timothy E Sullivan Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The Timothy E Sullivan Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein.
- [F2]This option was granted on February 16, 2018 and fully vested.
- [F3]This option was granted on February 8, 2019 and fully vested.